Novel hemostatic adhesive powder for nonvariceal upper gastrointestinal bleeding
Background and study aims A new hemostatic adhesive powder (UI-EWD) was developed to reduce high rebleeding rates and technical challenges associated with application of currently available hemostatic powders. The aim of the current study was to assess performance of UI-EWD for nonvariceal upper gas...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Georg Thieme Verlag KG
2019-12-01
|
Series: | Endoscopy International Open |
Online Access: | http://www.thieme-connect.de/DOI/DOI?10.1055/a-0982-3194 |
_version_ | 1818187485363044352 |
---|---|
author | Jin-Seok Park Hyung Kil Kim Yong Woon Shin Kye Sook Kwon Don Haeng Lee |
author_facet | Jin-Seok Park Hyung Kil Kim Yong Woon Shin Kye Sook Kwon Don Haeng Lee |
author_sort | Jin-Seok Park |
collection | DOAJ |
description | Background and study aims A new hemostatic adhesive powder (UI-EWD) was developed to reduce high rebleeding rates and technical challenges associated with application of currently available hemostatic powders. The aim of the current study was to assess performance of UI-EWD for nonvariceal upper gastrointestinal bleeding (NVUGIB).
Patients and methods A total of 56 consecutive patients that received UI-EWD monotherapy for endoscopic hemostasis due to NVUGIB were retrospectively reviewed. Main study outcomes were success rates with immediate hemostasis and rebleeding within 30 days. Outcomes were analyzed by reviewing patient medical records.
Results Etiologies of bleeding were: post-endoscopic therapy bleeding in 46 (82.1 %), peptic ulcer in 8 (14.3 %), tumor in 1 (1.8 %), and other in 1 (1.8 %). UI-EWD was successfully applied at bleeding site in all cases. The success rate of immediate hemostasis was 96.4 % (54/56), and the 30-day rebleeding rate among patients that achieved immediate hemostasis was 3.7 % (2/54). No adverse event related to use of UI-EWD occurred.
Conclusion UI-EWD was found to have a high immediate hemostasis success rate in NVUGIB when used as monotherapy and showed promising results in terms of preventing rebleeding. |
first_indexed | 2024-12-11T23:11:47Z |
format | Article |
id | doaj.art-6344774ea4fe49bca1392eb275dee346 |
institution | Directory Open Access Journal |
issn | 2364-3722 2196-9736 |
language | English |
last_indexed | 2024-12-11T23:11:47Z |
publishDate | 2019-12-01 |
publisher | Georg Thieme Verlag KG |
record_format | Article |
series | Endoscopy International Open |
spelling | doaj.art-6344774ea4fe49bca1392eb275dee3462022-12-22T00:46:41ZengGeorg Thieme Verlag KGEndoscopy International Open2364-37222196-97362019-12-010712E1763E176710.1055/a-0982-3194Novel hemostatic adhesive powder for nonvariceal upper gastrointestinal bleedingJin-Seok Park0Hyung Kil Kim1Yong Woon Shin2Kye Sook Kwon3Don Haeng Lee4Digestive Disease Center, Department of Internal Medicine, Inha University School of Medicine, Incheon, Republic of Korea Digestive Disease Center, Department of Internal Medicine, Inha University School of Medicine, Incheon, Republic of Korea Digestive Disease Center, Department of Internal Medicine, Inha University School of Medicine, Incheon, Republic of Korea Digestive Disease Center, Department of Internal Medicine, Inha University School of Medicine, Incheon, Republic of Korea Digestive Disease Center, Department of Internal Medicine, Inha University School of Medicine, Incheon, Republic of Korea Background and study aims A new hemostatic adhesive powder (UI-EWD) was developed to reduce high rebleeding rates and technical challenges associated with application of currently available hemostatic powders. The aim of the current study was to assess performance of UI-EWD for nonvariceal upper gastrointestinal bleeding (NVUGIB). Patients and methods A total of 56 consecutive patients that received UI-EWD monotherapy for endoscopic hemostasis due to NVUGIB were retrospectively reviewed. Main study outcomes were success rates with immediate hemostasis and rebleeding within 30 days. Outcomes were analyzed by reviewing patient medical records. Results Etiologies of bleeding were: post-endoscopic therapy bleeding in 46 (82.1 %), peptic ulcer in 8 (14.3 %), tumor in 1 (1.8 %), and other in 1 (1.8 %). UI-EWD was successfully applied at bleeding site in all cases. The success rate of immediate hemostasis was 96.4 % (54/56), and the 30-day rebleeding rate among patients that achieved immediate hemostasis was 3.7 % (2/54). No adverse event related to use of UI-EWD occurred. Conclusion UI-EWD was found to have a high immediate hemostasis success rate in NVUGIB when used as monotherapy and showed promising results in terms of preventing rebleeding.http://www.thieme-connect.de/DOI/DOI?10.1055/a-0982-3194 |
spellingShingle | Jin-Seok Park Hyung Kil Kim Yong Woon Shin Kye Sook Kwon Don Haeng Lee Novel hemostatic adhesive powder for nonvariceal upper gastrointestinal bleeding Endoscopy International Open |
title | Novel hemostatic adhesive powder for nonvariceal upper gastrointestinal bleeding |
title_full | Novel hemostatic adhesive powder for nonvariceal upper gastrointestinal bleeding |
title_fullStr | Novel hemostatic adhesive powder for nonvariceal upper gastrointestinal bleeding |
title_full_unstemmed | Novel hemostatic adhesive powder for nonvariceal upper gastrointestinal bleeding |
title_short | Novel hemostatic adhesive powder for nonvariceal upper gastrointestinal bleeding |
title_sort | novel hemostatic adhesive powder for nonvariceal upper gastrointestinal bleeding |
url | http://www.thieme-connect.de/DOI/DOI?10.1055/a-0982-3194 |
work_keys_str_mv | AT jinseokpark novelhemostaticadhesivepowderfornonvaricealuppergastrointestinalbleeding AT hyungkilkim novelhemostaticadhesivepowderfornonvaricealuppergastrointestinalbleeding AT yongwoonshin novelhemostaticadhesivepowderfornonvaricealuppergastrointestinalbleeding AT kyesookkwon novelhemostaticadhesivepowderfornonvaricealuppergastrointestinalbleeding AT donhaenglee novelhemostaticadhesivepowderfornonvaricealuppergastrointestinalbleeding |